Abstract
The question of combination versus single-agent chemotherapy in the setting of metastatic breast cancer (MBC) is an often-debated issue. Many single agents have activity in this setting and the potential for significant synergism between chemotherapy agents has led to many combination chemotherapy trials. This article defends the position that combination chemotherapy is the optimal approach for patients with MBC.
Original language | English (US) |
---|---|
Pages (from-to) | 673-675 |
Number of pages | 3 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 5 |
Issue number | 8 |
DOIs | |
State | Published - Sep 2007 |
Keywords
- Chemotherapy
- Combination therapy
- Metastatic breast cancer
- Polychemotherapy
- Single agent
ASJC Scopus subject areas
- Oncology